The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC)

Veenendaal, Linde M. van; Bertolli, Eduardo; Korse, Catharina M.; Klop, W. Martin C.; Tesselaar, Margot E. T.; Akkooi, A.C.J. van

doi:10.1245/s10434-020-08656-7

Cited by 20 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, small cell lung cancer patients with high NSE level have poor prognosis (25). Although it is concluded that both positive and negative NSE affects the short-term curative effect of patients and is related to the early recurrence, NSE content is not significantly related to clinical stage, tumor location, or T, N or TNM stage at the clinicopathological level, which is inconsistent with other research (24). The inconsistency may be related to the cut-off value of NSE.…”

Section: Discussionmentioning

confidence: 74%

“…This study demonstrates that the clinical CR or PR rate of pretreatment NSE-positive patients is significantly lower after radiotherapy and chemotherapy compared with pretreatment NSE-negative patients, and the short-term curative effect is poor. Similarly, NSE value is positively correlated with the load of Merkel cell carcinoma (24). Furthermore, small cell lung cancer patients with high NSE level have poor prognosis (25).…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

This study was aimed to evaluate the clinical values of single markers and combination in the diagnosis, short-term efficacy and recurrence risk assessment of esophageal squamous cell carcinoma (ESCC).MethodsTotally 50 patients with I-IVa stage ESCC, 50 healthy controls and 11 patients with recurrent esophageal cancer after comprehensive treatment were enrolled. Serum biomarkers were collected and evaluated. Serum concentrations of carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and neuron specific enolase (NSE) were measured by enzyme-linked immunosorbent assay before and after treatment.ResultsThe diagnostic efficacy ROC curve area of CEA, CYFRA21-1 and NSE in esophageal cancer was 0.70, 0.71 and 0.64(all P <0.05), respectively, the sensitivity was 80%, 88.89% and 60% respectively, and the specificity was 53%, 58.5% and 58% respectively. The sensitivity and specificity of the combined detection were 68% and 78% respectively. The area under ROC curve was 0.75. CEA, CYFRA21-1 and NSE were significantly higher than the healthy control group and thus can be used as diagnostic markers of esophageal cancer (all P <0.05). After standard treatment, the clinical CR and PR rate of patients with positive CYFRA21-1 or NSE before treatment was significantly lower than that of patients with negative CYFRA21-1 or NSE (X2 = 4.52,P =0.03). A significant negative correlation was found between N stage and clinical efficacy (HR 2.48, 95%CI 1.07-5.73). After comprehensive treatment, the serum CYFRA21-1 and NSE levels in recurrent patients also increased significantly(all P<0.05), indicating these two markers play obvious roles in recurrence monitoring.ConclusionCYFRA21-1 and NSE may help to predict the response of ESCC to CRT, and play important roles in the diagnosis and recurrence monitoring of esophageal cancer. These markers have a diagnostic value of esophageal cancer when combined with CEA.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 95%

Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Blood levels of NSE is increased in all stages of neuroblastoma, and greater increase has been linked to metastatic disease [91]. It is also increased in malignant pheochromocytoma [92,93], Guillain-Barré syndrome [94], Creutzfeldt-Jakob disease [95][96][97], carcinoid tumors [98], dysgerminomas [99,100], immature teratomas [101,102], Merkel cell tumor [103], melanoma [104], seminoma [105], renal cell carcinoma [106]. Among neurological diseases, increased NSE is associated with intracerebral hemorrhage [70,71], ischemic stroke [72][73][74][75][76], seizures [107,108], TBI [70,71,77], and comatose patients after cardiopulmonary resuscitation for cardiac arrest [109][110][111][112][113], newborns with perinatal hypoxic-ischemic encephalopathy [114][115][116], acute spinal cord injury [62,[117][118][119].…”

Section: Discussionmentioning

confidence: 99%

Role of neuron specific enolase as a biomarker in Parkinson’s disease

Dutta¹

2021

J Neurosci Neurol Disord

View full text Add to dashboard Cite

Parkinson’s disease (PD) is thought to be the most common neurodegenerative disease with movement disorder. The key motor symptoms are rigidity, tremor, akinesis/hypokinesia/bradykinesia, and postural instability. However, in our day-to-day clinical practice we tend to see several other symptoms which may be motor or non-motor. Non-motor symptoms (NMS) are quite common and debilitating. The pathological hallmarks of PD are loss of dopaminergic neurons in the substantia nigra pars compacta (SNPc) and accumulation of unfolded or misfolded alpha-synuclein. Diagnosis of PD is difficult in the pre-motor stage. Late diagnosis renders a substantial loss of dopaminergic neurons in SNPc and spread of disease in other parts of the brain. This may manifest as either full blown symptoms requiring multiple medications or may even lead to life threatening condition due to lack of early diagnostic tools and techniques. Biomarkers are required to diagnose PD at a very early stage when prevention is possible. Hence, we see a lot of interest among researchers involved in finding a biomarker specific to the disease. Biomarkers may be clinical, image based, genetic, and biochemical. Cerebrospinal fluid (CSF) and serum markers which may correlate with disease pathophysiology are of great significance. One such molecule which recently gained a lot of attention is neuron-specific enolase (NSE). The main aim of this paper is to highlight the role of NSE in predicting neurodegeneration and neuroinflammation ultimately reflecting damage of brain cells in PD.

show abstract

“…MCC is a neuroendocrine neoplasm and, accordingly, neuron-specific enolase (NSE) has been suggested as a possible biomarker. Although baseline NSE had no association with prognosis in a study of 84 patients, during immunotherapy ( n = 23) all those experiencing a CR ( n = 10) had normalized NSE (< 18.2 ng/mL) values, all those achieving a PR ( n = 5) had decreasing NSE levels, while all non-responders ( n = 8) had persistently elevated NSE concentrations [ 196 ].…”

Section: MCC Immunobiology and Tumor-specific Predictorsmentioning

confidence: 99%

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Zelin

Maronese

Dri

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Non-melanoma skin cancer (NMSC) stands as an umbrella term for common cutaneous malignancies, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together with rarer cutaneous cancers, such as Merkel cell carcinoma (MCC) and other forms of adnexal cancers. The majority of NMSCs can be successfully treated with surgery or radiotherapy, but advanced and metastatic stages may require systemic approaches such as immunotherapy with immune checkpoint inhibitors (ICIs). Summary: Since immunotherapy is not effective in all patients and can potentially lead to severe adverse effects, an important clinical question is how to properly identify those who could be suitable candidates for this therapeutic choice. In this paper, we review the potential features and biomarkers used to predict the outcome of ICIs therapy for NMSCs. Moreover, we analyze the role of immunotherapy in special populations, such as the elderly, immunocompromised patients, organ transplant recipients, and subjects suffering from autoimmune conditions. Key messages: Many clinical, serum, histopathological, and genetic features have been investigated as potential predictors of response in NMSCs treated with ICIs. Although this field of research is very promising, definitive, cost-effective, and reproducible biomarkers are still lacking and further efforts are needed to validate the suggested predictors in larger cohorts.

show abstract

The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC)

Cited by 20 publications

References 32 publications

Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma

Diagnostic, Prognostic, and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients With Esophageal Squamous Cell Carcinoma

Role of neuron specific enolase as a biomarker in Parkinson’s disease

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response

Contact Info

Product

Resources

About